These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 25439918)
1. Anti-inflammatory effects of orally administered glucosamine oligomer in an experimental model of inflammatory bowel disease. Azuma K; Osaki T; Kurozumi S; Kiyose M; Tsuka T; Murahata Y; Imagawa T; Itoh N; Minami S; Sato K; Okamoto Y Carbohydr Polym; 2015 Jan; 115():448-56. PubMed ID: 25439918 [TBL] [Abstract][Full Text] [Related]
2. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action. Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725 [TBL] [Abstract][Full Text] [Related]
3. Protective effect of marine mangrove Rhizophora apiculata on acetic acid induced experimental colitis by regulating anti-oxidant enzymes, inflammatory mediators and nuclear factor-kappa B subunits. V VP; C G Int Immunopharmacol; 2014 Jan; 18(1):124-34. PubMed ID: 24269623 [TBL] [Abstract][Full Text] [Related]
4. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Borrelli F; Fasolino I; Romano B; Capasso R; Maiello F; Coppola D; Orlando P; Battista G; Pagano E; Di Marzo V; Izzo AA Biochem Pharmacol; 2013 May; 85(9):1306-16. PubMed ID: 23415610 [TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory effects of methanol extract of Patrinia scabiosaefolia in mice with ulcerative colitis. Cho EJ; Shin JS; Noh YS; Cho YW; Hong SJ; Park JH; Lee JY; Lee JY; Lee KT J Ethnopharmacol; 2011 Jul; 136(3):428-35. PubMed ID: 20573566 [TBL] [Abstract][Full Text] [Related]
7. Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation. Zhang J; Ding L; Wang B; Ren G; Sun A; Deng C; Wei X; Mani S; Wang Z; Dou W J Pharmacol Exp Ther; 2015 Feb; 352(2):315-24. PubMed ID: 25472953 [TBL] [Abstract][Full Text] [Related]
8. Anti-tumor properties of orally administered glucosamine and N-acetyl-D-glucosamine oligomers in a mouse model. Masuda S; Azuma K; Kurozumi S; Kiyose M; Osaki T; Tsuka T; Itoh N; Imagawa T; Minami S; Sato K; Okamoto Y Carbohydr Polym; 2014 Oct; 111():783-7. PubMed ID: 25037416 [TBL] [Abstract][Full Text] [Related]
9. Chrysin, a natural flavone, improves murine inflammatory bowel diseases. Shin EK; Kwon HS; Kim YH; Shin HK; Kim JK Biochem Biophys Res Commun; 2009 Apr; 381(4):502-7. PubMed ID: 19233127 [TBL] [Abstract][Full Text] [Related]
10. Carboxyamidotriazole ameliorates experimental colitis by inhibition of cytokine production, nuclear factor-κB activation, and colonic fibrosis. Guo L; Ye C; Hao X; Zheng R; Ju R; Wu D; Luo L; Wang C; Li J; Yu X; Zhu L; Zhang D J Pharmacol Exp Ther; 2012 Aug; 342(2):356-65. PubMed ID: 22553216 [TBL] [Abstract][Full Text] [Related]
11. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease. Nakase H; Okazaki K; Tabata Y; Chiba T J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874 [TBL] [Abstract][Full Text] [Related]
12. Protective effect of 7-O-succinyl macrolactin A against intestinal inflammation is mediated through PI3-kinase/Akt/mTOR and NF-κB signaling pathways. Park S; Regmi SC; Park SY; Lee EK; Chang JH; Ku SK; Kim DH; Kim JA Eur J Pharmacol; 2014 Jul; 735():184-92. PubMed ID: 24769511 [TBL] [Abstract][Full Text] [Related]
13. Intestinal anti-inflammatory activity of luteolin: role of the aglycone in NF-κB inactivation in macrophages co-cultured with intestinal epithelial cells. Nishitani Y; Yamamoto K; Yoshida M; Azuma T; Kanazawa K; Hashimoto T; Mizuno M Biofactors; 2013; 39(5):522-33. PubMed ID: 23460110 [TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease. Gironella M; Iovanna JL; Sans M; Gil F; Peñalva M; Closa D; Miquel R; Piqué JM; Panés J Gut; 2005 Sep; 54(9):1244-53. PubMed ID: 15870231 [TBL] [Abstract][Full Text] [Related]
17. Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease. Ardite E; Panés J; Miranda M; Salas A; Elizalde JI; Sans M; Arce Y; Bordas JM; Fernández-Checa JC; Piqué JM Br J Pharmacol; 1998 Jun; 124(3):431-3. PubMed ID: 9647464 [TBL] [Abstract][Full Text] [Related]
18. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Ukil A; Maity S; Karmakar S; Datta N; Vedasiromoni JR; Das PK Br J Pharmacol; 2003 May; 139(2):209-18. PubMed ID: 12770926 [TBL] [Abstract][Full Text] [Related]
19. Intestinal alkaline phosphatase contributes to the reduction of severe intestinal epithelial damage. Bol-Schoenmakers M; Fiechter D; Raaben W; Hassing I; Bleumink R; Kruijswijk D; Maijoor K; Tersteeg-Zijderveld M; Brands R; Pieters R Eur J Pharmacol; 2010 May; 633(1-3):71-7. PubMed ID: 20132812 [TBL] [Abstract][Full Text] [Related]
20. Validation of bovine glycomacropeptide as an intestinal anti-inflammatory nutraceutical in the lymphocyte-transfer model of colitis. Ortega-González M; Capitán-Cañadas F; Requena P; Ocón B; Romero-Calvo I; Aranda C; Suárez MD; Zarzuelo A; Sánchez de Medina F; Martínez-Augustin O Br J Nutr; 2014 Apr; 111(7):1202-12. PubMed ID: 24229852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]